{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:16:35Z","timestamp":1793927795846,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92330-z","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:58:40Z","timestamp":1741795120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Analysis and mining of Dupilumab adverse events based on FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Hui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"2","key":"92330_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","volume":"69","author":"K Matsunaga","year":"2020","unstructured":"Matsunaga, K. et al. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int 69(2), 187\u2013196 (2020).","journal-title":"Allergol Int"},{"key":"92330_CR2","unstructured":"Holguin, F., et al. Management of severe asthma: A European respiratory Society\/American thoracic society guideline. Eur Respir J. 2020. 55(1)."},{"issue":"26","key":"92330_CR3","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378(26), 2486\u20132496 (2018).","journal-title":"N Engl J Med"},{"issue":"26","key":"92330_CR4","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe, K. F. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26), 2475\u20132485 (2018).","journal-title":"N Engl J Med"},{"issue":"2","key":"92330_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.anai.2019.04.028","volume":"123","author":"J Corren","year":"2019","unstructured":"Corren, J. et al. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol 123(2), 222-224.e1 (2019).","journal-title":"Ann Allergy Asthma Immunol"},{"key":"92330_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/JAA.S357548","volume":"15","author":"T Numata","year":"2022","unstructured":"Numata, T. et al. Real-world effectiveness of dupilumab for patients with severe asthma: A retrospective study. J Asthma Allergy 15, 395\u2013405 (2022).","journal-title":"J Asthma Allergy"},{"issue":"1","key":"92330_CR7","doi-asserted-by":"publisher","first-page":"2276043","DOI":"10.1080\/09546634.2023.2276043","volume":"34","author":"T Hagino","year":"2023","unstructured":"Hagino, T. et al. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J. Dermatol. Treatment 34(1), 2276043 (2023).","journal-title":"J. Dermatol. Treatment"},{"issue":"1","key":"92330_CR8","doi-asserted-by":"publisher","first-page":"2344591","DOI":"10.1080\/09546634.2024.2344591","volume":"35","author":"T Hagino","year":"2024","unstructured":"Hagino, T. et al. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. J. Dermatol. Treatment 35(1), 2344591 (2024).","journal-title":"J. Dermatol. Treatment"},{"key":"92330_CR9","doi-asserted-by":"crossref","unstructured":"Hagino, T., Saeki, H,, Fujimoto, E., et al. Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study. Clin. Exp. Dermatol., 2024: llae410.","DOI":"10.1093\/ced\/llae410"},{"issue":"4","key":"92330_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40261-024-01352-4","volume":"44","author":"T Hagino","year":"2024","unstructured":"Hagino, T. et al. Effectiveness of dose increase in upadacitinib from 15 mg to 30 mg for patients with moderate-to-severe atopic dermatitis: A Real-world clinical practice in Japan. Clin. Drug Investig. 44(4), 261\u2013269 (2024).","journal-title":"Clin. Drug Investig."},{"key":"92330_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu, H. et al. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. J. Affect. Disorders 347, 45\u201350 (2024).","journal-title":"J. Affect. Disorders"},{"issue":"1","key":"92330_CR12","doi-asserted-by":"publisher","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","volume":"14","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database. Sci. Rep. 14(1), 7659 (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"92330_CR13","doi-asserted-by":"publisher","first-page":"17138","DOI":"10.1038\/s41598-024-67627-0","volume":"14","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database. Sci. Rep. 14(1), 17138 (2024).","journal-title":"Sci. Rep."},{"key":"92330_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","volume":"354","author":"R Lu","year":"2024","unstructured":"Lu, R. et al. Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database. J. Affect. Disorders 354, 649\u2013655 (2024).","journal-title":"J. Affect. Disorders"},{"key":"92330_CR15","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","volume":"90","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Asian J. Psychiatry 90, 103828 (2023).","journal-title":"Asian J. Psychiatry"},{"key":"92330_CR16","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Du, Z., Shen, Y., et al. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur. Arch. Psychiatry Clin. Neurosci., 2023: 1\u20139.","DOI":"10.1007\/s00406-023-01732-5"},{"key":"92330_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J. Affect. Disorders 346, 223\u2013229 (2024).","journal-title":"J. Affect. Disorders"},{"key":"92330_CR18","doi-asserted-by":"crossref","unstructured":"Li, Z., Gu, J., Du, Z., et al. Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data. J. Affect. Disorders, 2025.","DOI":"10.1016\/j.jad.2025.01.022"},{"issue":"1","key":"92330_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","volume":"24","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Exploring adverse events of Vilazodone: Evidence from the FAERS database. BMC Psychiatry 24(1), 371 (2024).","journal-title":"BMC Psychiatry"},{"key":"92330_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jad.2024.07.034","volume":"362","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports. J. Affect. Disorders 362, 552\u2013559 (2024).","journal-title":"J. Affect. Disorders"},{"issue":"6","key":"92330_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/02698811241249651","volume":"38","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database. J. Psychopharmacol. 38(6), 567\u2013578 (2024).","journal-title":"J. Psychopharmacol."},{"key":"92330_CR22","doi-asserted-by":"crossref","unstructured":"Wang, Q., Qu, K., Du, Z., et al. Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database. J. Psychopharmacol., 2024: 02698811241248391.","DOI":"10.1177\/02698811241248391"},{"issue":"26","key":"92330_CR23","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378(26), 2486\u20132496 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"92330_CR24","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe, K. F. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 378(26), 2475\u20132485 (2018).","journal-title":"N. Engl. J. Med."},{"key":"92330_CR25","doi-asserted-by":"crossref","unstructured":"Alroobaea, R., Rubaiee, S., Hanbazazah, A. S., et al. IL-4\/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase\u2122): A big data and machine learning analysis. Eur. Rev. Med. Pharmacol. Sci. 2022, 26(11).","DOI":"10.2196\/preprints.33539"},{"key":"92330_CR26","unstructured":"Global Initiative for asthma. Global Strategy for Asthma Management and Prevention, 2021. www.ginasthma.org."},{"issue":"10196","key":"92330_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(19)31147-X","volume":"394","author":"K Huang","year":"2019","unstructured":"Huang, K. et al. Prevalence, risk factors, and management of asthma in China: A national cross-sectional study. Lancet 394(10196), 407\u2013418 (2019).","journal-title":"Lancet"},{"issue":"6","key":"92330_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/1753465816663978","volume":"10","author":"N Zhong","year":"2016","unstructured":"Zhong, N. et al. Uncontrolled asthma and its risk factors in adult Chinese asthma patients. Ther Adv Respir Dis 10(6), 507\u2013517 (2016).","journal-title":"Ther Adv Respir Dis"},{"issue":"5","key":"92330_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","volume":"15","author":"TA Wynn","year":"2015","unstructured":"Wynn, T. A. Type 2 cytokines: Mechanisms and therapeutic strategies. Nat Rev Immunol 15(5), 271\u2013282 (2015).","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"92330_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/cea.14112","volume":"52","author":"D Charles","year":"2022","unstructured":"Charles, D. et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. Clin Exp Allergy 52(5), 616\u2013627 (2022).","journal-title":"Clin Exp Allergy"},{"key":"92330_CR31","doi-asserted-by":"crossref","unstructured":"Petsky, H. L., Li, A. and Chang, A. B. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst. Rev., 2017. 8(8): CD005603.","DOI":"10.1002\/14651858.CD005603.pub3"},{"issue":"5","key":"92330_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","volume":"125","author":"WW Busse","year":"2020","unstructured":"Busse, W. W. et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol 125(5), 565-576.e1 (2020).","journal-title":"Ann Allergy Asthma Immunol"},{"key":"92330_CR33","unstructured":"Li Y, Lin H, Zhang Xn, et al. Preliminary clinical observation on the efficacy of Dupilumab in the treatment of severe asthma. Chin. J. Tuberculosis Respir. Dis. 2023, 46(9): 909\u2013915."},{"key":"92330_CR34","doi-asserted-by":"crossref","unstructured":"Mansilla-Polo, M., Morgado-Carrasco, D. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A narrative review. Dermatol. Ther. 2024, 14(8): 1983\u20132038.","DOI":"10.1007\/s13555-024-01203-2"},{"key":"92330_CR35","doi-asserted-by":"crossref","unstructured":"Alves, C., Penedones, A., Mendes, D., et al. The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. JCR: J. Clin. Rheumatol. 2022, 28(2): e407\u2013e414.","DOI":"10.1097\/RHU.0000000000001749"},{"issue":"5","key":"92330_CR36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo, C. E. et al. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol 84(5), 1339\u20131347 (2021).","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"92330_CR37","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","volume":"27","author":"E Shen","year":"2019","unstructured":"Shen, E. et al. Dupilumab-induced follicular conjunctivitis. Ocul Immunol Inflamm 27(8), 1339\u20131341 (2019).","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"92330_CR38","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","volume":"180","author":"DS Bakker","year":"2019","unstructured":"Bakker, D. S. et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180(5), 1248\u20131249 (2019).","journal-title":"Br J Dermatol"},{"issue":"2","key":"92330_CR39","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1111\/jdv.15914","volume":"34","author":"AN Voorberg","year":"2020","unstructured":"Voorberg, A. N. et al. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. J Eur Acad Dermatol Venereol 34(2), e64\u2013e66 (2020).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"92330_CR40","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdv.15608","volume":"33","author":"JP Thyssen","year":"2019","unstructured":"Thyssen, J. P. et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy-international eczema council survey and opinion. J Eur Acad Dermatol Venereol 33(7), 1224\u20131231 (2019).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"92330_CR41","doi-asserted-by":"crossref","unstructured":"Bangert, C., et al., Persistence of mature dendritic cells, T(H)2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Ralpha blockade. Sci. Immunol. 2021. 6(55).","DOI":"10.1126\/sciimmunol.abe2749"},{"issue":"11","key":"92330_CR42","first-page":"4074","volume":"26","author":"R Alroobaea","year":"2022","unstructured":"Alroobaea, R. et al. IL-4\/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase): A big data and machine learning analysis. Eur Rev Med Pharmacol Sci 26(11), 4074\u20134081 (2022).","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92330-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92330-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92330-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:58:49Z","timestamp":1741795129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92330-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92330"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92330-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8597"}}